🎉 M&A multiples are live!
Check it out!

Scilex Holding Valuation Multiples

Discover revenue and EBITDA valuation multiples for Scilex Holding and similar public comparables like Julphar, Benevolent AI, and Pharming.

Scilex Holding Overview

About Scilex Holding

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.


Founded

2009

HQ

United States of America
Employees

115

Financials

LTM Revenue $79.2M

LTM EBITDA n/a

EV

$69.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Scilex Holding Financials

Scilex Holding has a last 12-month revenue of $79.2M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Scilex Holding achieved revenue of $56.6M and an EBITDA of -$66.8M.

Scilex Holding expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Scilex Holding valuation multiples based on analyst estimates

Scilex Holding P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $46.7M $56.6M XXX XXX XXX
Gross Profit $27.2M $31.1M XXX XXX XXX
Gross Margin 58% 55% XXX XXX XXX
EBITDA -$109M -$66.8M XXX XXX XXX
EBITDA Margin -233% -118% XXX XXX XXX
Net Profit -$23.4M -$114M XXX XXX XXX
Net Margin -50% -202% XXX XXX XXX
Net Debt n/a $122M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Scilex Holding Stock Performance

As of April 15, 2025, Scilex Holding's stock price is $7.

Scilex Holding has current market cap of $34.5M, and EV of $69.2M.

See Scilex Holding trading valuation data

Scilex Holding Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$69.2M $34.5M XXX XXX XXX XXX $-0.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Scilex Holding Valuation Multiples

As of April 15, 2025, Scilex Holding has market cap of $34.5M and EV of $69.2M.

Scilex Holding's trades at 0.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Scilex Holding's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Scilex Holding and 10K+ public comps

Scilex Holding Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $69.2M XXX XXX XXX
EV/Revenue 1.2x XXX XXX XXX
EV/EBITDA -1.0x XXX XXX XXX
P/E -0.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 3.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Scilex Holding Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Scilex Holding Valuation Multiples

Scilex Holding's NTM/LTM revenue growth is 83%

Scilex Holding's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Scilex Holding's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Scilex Holding's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Scilex Holding and other 10K+ public comps

Scilex Holding Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 21% XXX XXX XXX XXX
EBITDA Margin -118% XXX XXX XXX XXX
EBITDA Growth -39% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -35% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 17% XXX XXX XXX XXX
Opex to Revenue 234% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Scilex Holding Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Scilex Holding M&A and Investment Activity

Scilex Holding acquired  XXX companies to date.

Last acquisition by Scilex Holding was  XXXXXXXX, XXXXX XXXXX XXXXXX . Scilex Holding acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Scilex Holding

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Scilex Holding

When was Scilex Holding founded? Scilex Holding was founded in 2009.
Where is Scilex Holding headquartered? Scilex Holding is headquartered in United States of America.
How many employees does Scilex Holding have? As of today, Scilex Holding has 115 employees.
Who is the CEO of Scilex Holding? Scilex Holding's CEO is Mr. Jaisim Shah.
Is Scilex Holding publicy listed? Yes, Scilex Holding is a public company listed on NAS.
What is the stock symbol of Scilex Holding? Scilex Holding trades under SCLX ticker.
When did Scilex Holding go public? Scilex Holding went public in 2022.
Who are competitors of Scilex Holding? Similar companies to Scilex Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Scilex Holding? Scilex Holding's current market cap is $34.5M
What is the current revenue of Scilex Holding? Scilex Holding's last 12-month revenue is $79.2M.
What is the current EV/Revenue multiple of Scilex Holding? Current revenue multiple of Scilex Holding is 0.9x.
What is the current revenue growth of Scilex Holding? Scilex Holding revenue growth between 2023 and 2024 was 21%.
Is Scilex Holding profitable? Yes, Scilex Holding is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.